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Heavy metals including mercury, lead, and cadmium are present throughout the ecosystem and
are detectable in small amounts in the Great Lakes water and fish. The main route of exposure of
humans to these metals is via the ingestion of contaminated food, especially fish. Extensive
experimental investigations indicated that heavy metals alter a number of parameters of the
host's immune system and lead to increased susceptibility to infections, autoimmune diseases,
and allergic manifestations. The existing limited epidemiologic data and data derived from in vitro
systems in which human peripheral blood leukocytes were used suggested that the human
immune system may also be at increased risk following exposure to these metals. The magnitude
of the risk that the presence of such metals in the Great Lakes may pose to the human immune
system, and consequently to their health, is not known. In this review, the available data with
respect to potential adverse effects of heavy metals on the immune system of humans and
experimental animals are discussed, and additional data requirements are suggested. Environ
Health Perspect 103(Suppl 9):23-34 (1995)
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Introduction
Metals, including mercury (Hg), lead (Pb),
and cadmium (Cd), are chemicals (ele-
ments) released into the environment fol-
lowing medical and industrial use and
leakage from dump sites (1). Once released
into the environment, metals in various
forms will contaminate the air, soil, water,
and food. Trace amounts of these metals
are detected as contaminants in several
parts ofthe ecosystem including the North
American Great Lakes basin (2). Although
their concentrations in the Great Lakes are
small (Table 1) (2), they bioaccumulate in
small fish and other biota present in the
Great Lakes. Larger fish, feeding on these
smaller fish, accumulate these metals in
Table 1. Concentrations of mercury, lead, and cad-
mium in the Great Lakes water (ppt).
Metal
Lake Mercury Lead Cadmium
Superior 98 39 27
Huron 60 38 16
Michigan 52 260 42
Erie 42 910 98
Data from Rossman and Barres (2).
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their body tissues and retain them for long
periods of time (3,4). Humans are con-
stantly exposed to low levels ofthese metals
present in air, water, and food. In addition,
certain populations, especially those who
consume large amounts of fish, may accu-
mulate in their tissues levels that are poten-
tially harmful to their health and the health
of their offspring (5). Studies in experi-
mental animals and the existing scanty epi-
demiologic data in occupationally exposed
cohorts support the view that exposure to
metals may compromise the host's immune
system, leading to increased susceptibility
to infections and the development of
autoimmune diseases (5,6).
In view of these concerns, a review of
the existing data regarding the potential
immunomodulatory effects of mercury,
lead, and cadmium was undertaken. The
main objective of this review was to iden-
tify areas of research for which our knowl-
edge, with respect to parameters of the
immune system affected by metals and the
mechanisms involved, is insufficient for
regulatory purposes.
General Comments
Heavy metals are known to elicit a number
of immunomodulatory effects ultimately
leading to an enhanced susceptibility to
microbial agents and to the appearance of
neoplastic diseases and autoimmune phe-
nomena (5-8). The severity ofthese effects
depends largely on the animal species and
strain used, the route and duration ofexpo-
sure, and the metal species employed.
Using the mouse as the animal model
and the plaque-forming cell (PFC) response
to sheep red blood cells (SRBC) as an indi-
cator ofimmunotoxicity, Lawrence (9) was
able to rank heavy metals for their immuno-
toxic properties in the following order: mer-
cury > copper > manganese > cobalt >
cadmium > chromium. Zinc and iron had
no significant effects, while lead and nickel
resulted in a significant increase ofthe PFC
numbers. It is ofinterest that some ofthese
heavy metals, notably zinc and copper as
trace elements, are considered to be essential
for proper body functions (10).
The mechanism(s) that mediate the
immunomodulatory effects of metals are
not fully elucidated. It has been suggested
that metallothioneins (MTs) may play a
role in the immunosuppressive properties
ofheavy metals. MTs are small cysteine-
rich proteins (6-8 kDa) that bind heavy
metals (11). They are induced following
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exposure to metals and play a role in the
homeostatic regulation of essential metals
and probably in the detoxification of
heavy metals (11,12). Cadmium chloride
(CdCI2), as well as mercuric chloride
(HgCl2), induced thionein production in a
dose-dependent fashion in human periph-
eral blood lymphocytes (PBL) (12,13).
However, the concentration required for
thionein induction varied among metal
species (14), although no apparent differ-
ences were noted in the pattern of the
induced thionein isoforms (14). In mouse
splenocytes, CdCI2 was the more potent
inducer of MTs followed by HgCl2 and
lead chloride (PbCI2) (15), while lead
acetate [(C2H302)2Pb] did not induce any
MT in human PBL (14). The induction of
MT is not restricted to metals since stimula-
tion ofmouse splenocytes with the mitogen
concanavalin A (ConA) or lipopolysac-
charide (LPS) had similar effects (15).
These results taken together suggested that
induction of MT might be related to the
metabolic state of the cell and that the
observed quantitative differences in the
induction of MT by some metals may
partly explain the variability of the
immunotoxic effects obtained following in
vivo exposure to these metals (16).
Additional mechanistic studies are required
to firmly establish the potential relation-
ship between the induction of MTs by
metals and effects on the immune system.
Mercury
EpidemiologicStudies ofHg
The elemental form ofHg occurs naturally
in the environment. Once released into the
environment, Hg may combine with other
elements to form inorganic and organic Hg
compounds. Estimated levels of Hg in
Great Lakes fish range from 0.14 to 0.32
pg/g for commercial fish taken from the
four Great Lakes bordering Canada and
have reached 0.5 pg/g as reported in a sur-
vey of valleys from northern Wisconsin
Lakes (17). Higher levels of 1.21 mg/kg
dry weight or 0.35 mg/kg based on a wet
tissue basis were reported for Lake Ontario
salmon (18). Methylmercury (MeHg) is of
particular concern to human health since it
is the most toxic form of Hg (19). Long-
term exposure to Hg may result in irre-
versible damage to brain, kidneys, and the
developing fetus (19). Consequently, a
large database exists regarding toxicologic
effects ofHg, particularly effects associated
with neurobehavioral abnormalities (19,20).
Based on these data, the joint Food and
Agriculture Organization/World Health
Oranization Expert Committee on Food
Additives has estimated a permissible toler-
able weekly intake for MeHg of 3.3
pg/kg/week equivalent to 4.7 x 10-4
mg/kg/day (0.47 pg/kg/day) (19,20). The
U.S. Environmental Protection Agency
(U.S. EPA) has derived a reference dose
(RfD) for MeHg, which equals 3 x 10-4
mg/kg/day (0.3 pg/kg/day) (21). For a
generic 70-kg adult, this is equivalent to a
daily intake of 21 pg/day, and for a 62-kg
woman, this dose is equivalent to an intake
of 19 pg/day. Recently, an RfD =
0.07 pg/kg/day was suggested by Stern
(22) based on developmental effects.
The contribution of the Great Lakes
fish to the overall human burden ofHg is
not known. Preliminary results ofan ongo-
ing study (Kearney et al., personal commu-
nication) suggested that Great Lakes
fish-eating cohorts may have higher blood
MeHg levels than non-Great Lakes fish
eaters. In this study, the concentrations of
Hg were examined in 232 participants of
which 176 were sport fish eaters (152 were
Great Lakes fish eaters, 24 consumed only
non-Great Lakes fish) and 56 were sport
fish noneaters. Higher blood Hg levels were
reported for the 176 sport-fish eaters (geo-
metric mean = 2.2 [2.0 ppb] with a range
of <2-17 ppb) compared to the 56 sport
fish noneaters (geometric mean = 1.6 [1.8]
with a range of <2-6 ppb) (Kearney et al.,
personal communication).
In contrast to the existing large database
for neurotoxic effects of Hg, only limited
data exist in humans while data on the
immune effects of Hg in fish-eating popu-
lations are nonexistent.
Hg concentrations in the blood and
urine, as well as total serum immunoglobu-
lins (Ig), were measured in 89 male work-
ers occupationally exposed to Hg vapors
for 2 to 26 years (mean 13.6) (23). The
blood Hg concentration did not exceed 50
pg/l (50 ppb) in any ofthe subjects studied.
Hg concentrations in urine greater than
200 pg/l were measured in only 2 of the
workers. Significantly decreased serum IgG
and IgA, but not IgM, IgD, and IgE, were
reported only for those workers who were
exposed to metallic Hg vapors for more
than 20 years compared to an unexposed
reference group (23). However, there was
no correlation between the immunoglobu-
lin concentration and duration ofexposure
or Hg concentration in the body fluids
(23). Likewise, the incidence ofupper res-
pirafry and urinary tract infections in the
exposed group was not different than that
in the reference group (23). In contrast,
increased IgG, but not IgA and IgM, levels
were observed in workers with urinary Hg
levels of29 to 545 pg/l (29-545 ppb) (24).
Oral galvanism is associated with low-
dose exposure of metallic Hg vapor from
amalgam fillings (24) and is perhaps the
second most important source ofmercury,
contributing approximately 0.9 tol7.5 pg
to the total body burden (25). For com-
parison, Sweden has set a threshold limit
for metallic Hg vapor in the work environ-
ment equal to 50 pg/m3 corresponding to
an exposure of approximately 500 pg/dl
(25). Decreased serum IgE levels and
increased complement (C3d) levels were
reported in a study of a small number of
humans exposed to Hg in dental amalgams
(26). The reduced IgE levels were observed
during the period following removal ofthe
dental amalgam, and it may have been an
indication ofa noncompensated consump-
tion ofIgE that might have occurred dur-
ing the postexperimental period (26).
Aggravation ofasthma due to Hg in dental
amalgams has been reported for one patient
(27). On the contrary, no association was
found between the number of amalgam
tooth fillings and the prevalence ofasthma,
eczema, and allergic rhinoconjuntivitis in
348 Swedish adolescent schoolchildren
(28), albeit a significant correlation could
be identified between the number ofamal-
gam surfaces and plasma Hg levels in a sub-
group of these children (29). The latter
included 21 schoolchildren (15 years old)
with amalgams and 20 without amalgams.
There were no significant differences
between the two groups in several of the
parameters tested including T- and B-lym-
phocyte levels, T-cell subsets, Ig levels (IgG,
IgGI, IgG3, IgG4, IgA, IgM, and IgE), and
antinuclear antibodies (29). The median for
plasma mercury concentration was 1.65 and
2.10 nmol/l for males and females, respec-
tively (28). In contrast, increased total lym-
phocyte, T helper/inducer (CD4+), and T
suppressor/cytotoxic (CD8+) levels were
reported in a group of 25 dental students
(average age of21.5 years) who were pre-
sumably occupationally exposed to Hg,
compared with a reference group ofmedical
students (30). However, the significance of
these results is not clear from the data pre-
sented since the CD4+:CD8+ ratio, or the
peripheral blood B-lymphocyte (CD21+)
levels and natural killer (CD16+) cells did
not differ between the two groups.
Similarly, there was no evidence of Hg-
induced cutaneous hypersensitivity
reactions in the two groups tested (30).
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Concentrations of Hg in tissues were not
reported for these students.
Finally, the incidence ofallergic contact
dermatitis to a number ofmetals including
Hg was studied in 329 Portuguese children
of 14 years ofage or younger. These chil-
dren were patch tested by members ofthe
Portuguese Contact Dermatitis Group
between 1985 and 1989 (31). An incidence
of6.1% positive patch tests to ammoniated
Hg was reported in these children, with the
number of positive reactions increasing
with age (31).
Overall, these data suggested that Hg,
at levels found in occupational exposures,
may have an adverse effect on the immune
system of humans. Decreased levels of
serum immunoglobulins were observed in
occupationally exposed cohorts with blood
Hg levels <50 pig/l, but a concurrent
increase in the incidence of microbial
infections was not observed in these work-
ers. The reviewed data also suggested that
Hg has the potential of eliciting contact
sensitization in children with a genetic pre-
disposition to allergy; further carefully
designed epidemiologic studies are needed
to establish the potential role Hg may play
in eliciting such reactions.
Experimenal Studies in Vivo
Inorganic and organic forms of Hg have
definite cytotoxic effects on cellular com-
ponents of the immune system. HgCI2
administered orally to B6C3F1 mice at
doses of 75 ppm for 7 days resulted in
significantly reduced spleen and thymus
weights compared to the control (32). A
no observed adverse effect level (NOAEL)
dose of 15 ppm was reported for these
mice (32). Reduced thymus weight was
also reported in BALB/c mice administered
MeHg orally at a dose of 3.9 ppm for 12
weeks (33). A progressive systemic lym-
phadenopathy was observed in brown
Norway (BN) rats following exposure to
HgCI2 with a 3-fold increase in the weight
ofthe lymph nodes (34).
The potential role ofHg in the develop-
ment ofautoimmunity was studied in genet-
ically susceptible mice and rats (35-42). In
these animals, systemic autoimmune dis-
eases were induced by repeated injections
ofHgCl2. Several Hg-induced autoimmune
phenomena, including the presence of
antibasement membrane, antinucleolar and
antinuclear antibodies, and the development
ofglomerulonephritis were observed in
genetically susceptible animals (39-53).
These phenomena are thought to be a result
ofa dysregulation ofT lymphocytes, which
might involve the induction ofa T-depen-
dent polyclonal activation of B cells
(39-53). This would account for the devel-
opment ofthe various autoantibodies (54)
and the observed increased production of
total serum IgE and IgG1 in mice and rats
following exposure to HgCl2 (50,54,55).
Hg-induced autoimmune disorders are
thought to be linked to the major histo-
compatibility complex (MHC) (35,39,41,
56,57). Indeed, the development ofautore-
active CD4+ (T-helper/inducer) cells with
the ability to proliferate in the presence of
normal syngeneic cells that express MHC
class II antigens is well documented in
HgCI2-treated rats (58). Hg-specific T cells
were detected in HgCl2-treated mice, but
their role in the development of autoim-
munity is not clear (40). Fluctuations in
the number ofCD8+, MHC class-II+, and
interleukin-2 receptor positive (IL-2R+)
cells were also observed in the secondary
lymphoid organs of HgCl2-exposed rats
but no overall uniform effects could be
identified (39,41).
MeHg may affect nonspecific host
defense mechanisms since it has been
shown to decrease the natural killer (NK)
cell activity in rats exposed in utero and
through milk to 3.9 j'g/g (3.9 ppm) ofthe
dam's feed (59) and in mice following
oral administration of the same dose over
a 12-week period (33).
The effects of MeHg on humoral
immune responses are well documented.
MeHg at a single dose of 10 ppm adminis-
tered orally for 10 weeks resulted in
decreased antibody levels to pseudorabies
and influenza viruses in the rabbit with a
NOAEL of 1 ppm (60). Likewise, HgCl2
at doses of250 and 500 ppm administered
to chickens orally for 35 days or at 300
pg/ml for 11 weeks diminished their ability
to produce specific IgM and IgG antibodies
to SRBC (61,62). A NOAEL of 125 ppm
was observed in chickens. A greater sensitiv-
ity to HgCl2 was observed in B6C3Fi mice
administered doses of 3,15, or 75 ppm
orally for 7 weeks, with a lowest observed
adverse effect level (LOAEL) of75 ppm and
a NOAEL of 15 ppm (32). The PFC
response to LPS-a B-cell-dependent anti-
gen-was not affected by any ofthese doses
(32). More over, reduced PFC responses to
SRBC were obtained when different strains
ofmice were treated with low doses (1, 5, or
10 ppm) of MeHg (63,64). A LOAEL
value of1 ppm was identified forMeHg.
Hg has the potential for eliciting contact
sensitization as revealed by the classical
maximization test in the guinea pig (65)
and allergic contact dermatitis in mice (66).
The significance of these findings is not
clear since no such effects were noted in
occupationally exposed cohorts (29), albeit
contact sensitization was detected in chil-
dren when these were patch tested with
ammoniated Hg (31). The effects of
MeHg on the mitogen-induced prolifera-
tive ability of leukocytes varied with the
mitogen used. In B6C3Fi mice following
treatment with 15 or 75 ppm ofMeHg for
7 weeks, decreases in the lymphoprolifera-
tive activity ofsplenocytes in response to
phytohemagglutinin (PHA) and ConA
mitogens were observed, whereas the
response to LPS was enhanced significantly
(32). A lower dose of 5 ppm of MeHg
either enhanced or had no effect on the
ConA-induced proliferative activity (67).
Similarly, doses of 1, 5, or 10 ppm admin-
istered to C57BI/6 mice for 7 weeks did
not affect the mixed lymphocyte culture
(MLC) response (68). A LOAEL of 15
ppm and a NOAEL of 5 ppm were
identified in mice.
In summary, the existing experimental
animal data permits the derivation of
LOAELs in some species, but the obvious
lack of data pertaining to tissue levels of
Hg in these animals and the use ofsingle
versus multiple' doses in some ofthe stud-
ies diminishes the merit of such data for
regulatory purposes. Nevertheless, the
LOAELs derived from such data clearly
indicate that both forms of Hg can be
immunotoxic at the levels tested and that
MeHg is immunotoxic at levels lower than
those observed for HgCI2 (Table 2).
In VtroMechanisticStudies ofHg
The in vitro cytotoxicity of MeHg was
shown to be 10-fold higher than that of
HgCl2, with human peripheral blood
monocytes exhibiting a significantly greater
sensitivity to both forms of Hg than lym-
phocytes (69,70). The median lethal dose
(LD50) values for HgCI2 were 23 and 4
pM for human T cells and monocytes,
respectively, and 6.0 and 0.4 pM for
MeHg for T cells and monocytes, respec-
tively (70). The observed cell cytotoxicity
involved an apoptotic process suggesting
that Hg may activate the cellular signaling
pathway, which leads to the suicide ofcells
(70). Human peripheral blood T cells and
monocytes in the presence of either form
ofHg exhibited a decreased 32p incorpora-
tion into phospholipids (69). The observed
decrease was associated with a concurrent
increase in intracellular calcium levels
characteristic ofthe apoptotic process (69).
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Table2. LOAELs and NOAELs for immunotoxic effects of mercury.
Route of LOAEL, NOAEL,
Metal Species exposure ppm ppm Effect Reference
MeHg Rabbit Oral 10 1 Reduced antibody levels to viruses (60)
MeHg Mouse Oral 3.9 1 Reduced thymus weight and NK activity (59)
MeHg Mouse Oral 1 - Reduced SRBC-PFC (60-64)
MeHg Mouse Oral 15 - Reduced LTto PHAand ConA (32)
HgCI2 Chicken Oral 250 125 Reduced SRBC-PFC (61,62)
HgCI2 Mouse Oral 3.9 3.0 Reduced thymus and spleen weight (32)
HgCI2 Mouse Oral 75 15 Reduced SRBC-PFC (32)
Abbreviations: LOAEL, lowest observed adverse effect level; NOAEL, no observed adverse effect level; NK, natural
killer cell; SRBC-PFC, sheep red blood cells-plaque-forming cell assay; LT, lymphocyte transformation; PHA, phyto-
hemagglutinin; ConA, concanavalin A; MeHg, methylmercury; HgCI2, mercuricchloride.
At noncytotoxic levels, HgCI2 decreased
the functional activity ofeither polymor-
phonuclear cells or monocytes isolated from
human peripheral blood (70). Interestingly,
a higher level ofsuperoxides (H202) pro-
duction was observed in peptone-induced
murine peritoneal macrophages upon incu-
bation with Hg, suggesting that activated
macrophages may be less susceptible to the
effects ofthis metal (70).
In vitro treatment ofSJL mouse spleno-
cytes with Hg increased the response to B-
and T-cell mitogens, whereas under the
same experimental conditions, DBA mouse
cells showed a significant reduction in their
proliferative ability (67). The latter effects
were optimal at low doses ofHgCl2 (10-7,
10-8 M) and were observed only when the
mercury was added as a pulse 1 hr before
the addition ofthe mitogen suggesting that
lymphocyte susceptibility may be linked to
the MHC (67).
Additional in vitro studies demon-
strated that the observed Hg-related
decrease in ConA-induced T-cell prolifera-
tion was associated with a decrease in phos-
phatidylinositol levels (71). Moreover, it
was demonstrated that Hg did not change
the expression ofCD69, an early marker of
cell activation, but significantly reduced
expression ofthe IL-2R (70). These results
suggested that following the stimuli, very
early events in the G1 phase were not
affected by Hg, but later G1 events were
perturbed (67). An increase ofintracellular
calcium was observed in human peripheral
blood leukocytes exposed for 5 min to Hg
(70). The calcium flux was not mediated
bycalcium-specific channels since the addi-
tion ofchannel blockers, such as verapamil
and nifedipine, failed to alter Hg-induced
changes in calcium fluorescence (70). On
the other hand, incubation for 1 hr with
various concentrations of Hg caused an
increase oftyrosine-phosphorylated pro-
teins and p561ck kinase activity as well as
an increase of phosphatase activity (72).
These results taken together demonstrated
that mercury could modulate cellular sig-
naling pathways; however, the degree to
which these changes influence the integrity
of the immune system is not well under-
stood. Therefore, further investigations are
required to completely elucidate the mech-




The main target ofPb toxicity is the ner-
vous system, especially in children (73,74).
Exposure to Pb has also been associated
with increased blood pressure in adult popu-
lations (73) and is causally related to
nephropathies in children and in adults
(74). While water analysis studies suggested
that Pb levels in the Great Lakes may not
exceed the 10 pg/l guideline set by the
Canadian Health Department for Pb levels
in drinking water (17) (Table 1), different
forms ofPb bioaccumulate in fish (18) and
in humans, especially those who are fre-
quent fish eaters. Preliminary results ofan
ongoing study suggested that Pb levels
might be higher in cohorts who consumed
Great Lakes fish (mean 3.7 mg/dl, range
1.1-26.8 mg/dl) compared to those who
did not consume Great Lakes fish (mean 3.0
mg/dl, range <0.5-10.7 mg/dl) (Kearney et
al., personal communication).
Epidemiologic data following occupa-
tional exposure to Pb suggest that the main
effects ofPb might be on cellular aspects of
the immune system with humoral parame-
ters remaining relatively insensitive to Pb
exposure. Thus, serum Igs (IgG, IgM, and
IgA) remained within normal levels in
workers occupationally exposed to Pb for
4 to 30 years (75). The exposed workers
had a mean blood lead level of38.4 pg/dl
compared to the control mean levels of
11.8 pg/dl. Similarly, no effects were
noted on serum IgG and IgA levels in
another cohort occupationally exposed to
lead oxides with estimated blood Pb levels
of64 pg/dl. The Pb oxides concentration
within the plant was 266 pg/m3 (75). The
in vitro response of PBL to PHA and
ConA stimulation was significantly
decreased in the exposed group compared
to the control (76). A decrease in serum Ig
levels was reported in 14 occupationally
exposed workers with blood Pb levels of
46.9 pg/dl. The duration of exposure of
these workers was 36 years (77). The con-
trol (nonexposed) group had mean blood
Pb levels of 10.9 pg/dl. While no
significant effects were noted on serum Ig
levels in 72 occupationally exposed work-
ers compared to 53 reference subjects, the
levels of secretory (salivary) IgA were
significantly decreased in the exposed
group (78). The exposed group had
significantly higher blood Pb levels (21-90
pg/dl; mean = 51 pg/dl) compared to
those of the reference group (mean = 12
pg/dl) (78). Secretory IgA plays a major
role in the defense against respiratory, and
gastrointestinal infections and the observed
reduced levels might be responsible for the
increased incidence ofinfluenza infections
reported in the exposed workers compared
to that in the reference group (78). In the
same study, complement (C3) levels were
not significantly different between the two
groups but significant negative correlations
were detected between Pb levels in the
blood and C3 levels. Similarly negative cor-
relations were observed between blood Pb
levels and total serum IgG levels, while a
positive correlation was obtained between
the blood Pb level and serum IgA levels
(78). Positive correlations between blood Pb
levels and serum IgA were also detected in a
group of Pb refinery workers whose blood
Pb levels were greater than 60 pg/dl (79).
Data regarding the effects ofPb on the
numbers and function oflymphocytes and
their subsets are available only for a small
number ofoccupationally exposed workers.
These data are generally based on one-time
analysis and are therefore not easily inter-
pretable regarding theirclinical significance.
In one such study 10 Pb-exposed subjects
(range ofblood Pb levels = 40-51 pg/dl)
were compared to 10 reference subjects
(blood Pb levels <19 pg/dl). This study did
not report any significant differences
between the two groups regarding the levels
ofT lymphocytes and their subsets or T-
lymphocyte function in the mitogen
induced proliferation assay (80). A second
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study involved two groups of firearms
instructors (81): group 1 (high) had mean
blood Pb levels of 31 pg/dl while group 2
(low) had mean blood Pb levels of15 pg/dl.
A significant decrease in the CD3+ (total
lymphocytes) attributable to a decrease in
the CD4+ T-cell subset was detected for the
high-exposure group compared to the low-
exposure group. This may have accounted
for the observed functional impairment of
cell-mediated immunity that was assessed by
the response oflymphocytes to T-cell mito-
gens and by the mixed lymphocyte culture,
both ofwhich require T-helper activity.
Other cell types including the CD8+, the B-
lymphocyte (CD20+), or the NK cells
(CD16+) were not altered significandy (81).
The effects of Pb on immune parame-
ters were also investigated in 12 preschool-
age children with evidence of Pb toxicity
(mean blood Pb levels = 45 pg/dl) com-
pared to 7 children with mean blood Pb
levels = 23 pg/dl (82). There were no
significant differences between the two
groups regarding total serum Ig levels,
complement levels, and their ability to
respond to a recall antigen such as the
tetanus toxoid (82). The absence of
significant differences between the two
groups may be attributed to the fact that Pb
levels in the low-exposure group were above
the published standard of>10 IOg/dl for Pb
intoxication (83). In this case, correlations
between blood Pb levels across all 19 chil-
dren and the parameters measured might
have been more revealing.
In summary, data derived from studies
in epidemiologically exposed cohorts sug-
gested that Pb may affect the immune sys-
tem; however, only general parameters,
including effects of Pb on serum Ig levels
and peripheral blood leukocyte counts,
have been examined in these studies. The
absence ofdata on more clinically relevant
parameters, such as on functional aspects of
the immune system, and the lack of
repeated measures ofthe affected parame-
ters do not allow for a complete evaluation
ofthe potential immunotoxic effects ofPb
in humans. The observed NOAELs and
LOAELs based on blood Pb levels and the
associated effect on immune parameters are
as follows: LOAEL = 46.9 pg/dl based on
decreased serum Ig levels with a NOAEL of
38.4 lig/dl; LOAEL = 64 pg/dl based on
reduced lymphoproliferative activity ofPBL
in response to mitogens; and a LOAEL =
31 pg/dl based on decreased total T lym-
phocytes and T-helper/inducer cells with a
NOAEL <19 pg/dl. It is apparent from
these data that potentially adverse
immunologic effects of Pb were noted at
blood Pb levels much lower (parts per bil-
lion) than those detected in the Great Lakes
fish-eating cohorts (ppm) (22). Data
regarding the immunological status ofthe
latter group are not presently available.
Thus, an evaluation ofthe consequences of
such levels on the immune system of the
Great Lakes fish-eating cohorts would
require the evaluation ofdata derived from
carefully designed studies whereby quanti-
tative and functional aspects ofthe immune
system would be investigated.
Experimental Studies ofPb in Vivo
The effects of Pb on the immune system
ofexperimental animals are as divergent as
those reported for Hg (6,7). Pb effects on
rat organ weights including the thymus,
spleen, and popliteal lymph nodes have
been reported but these are not dose
related (84,85).
Effects on total serum immunoglobulin
levels and on the antibody response to
specific antigens have also been reported.
Rats exposed in utero and postnatally to 25
or 50 ppm ofPb had significantly decreased
serum IgG levels while IgA and IgM were
not affected (86).
Effects ofPb on humoral aspects ofthe
immune system have been reported by sev-
eral investigators, but no clear picture
emerges through these data regarding the
potential effects of Pb. For example,
(C2H302)2Pb administered to mice in
drinking water at concentrations ranging
from 0.08 to 50 mM of Pb for 1 or 10
weeks did not affect the spleen PFC num-
bers to SRBC (87), whereas the in vitro
primary response to SRBC assessed in lym-
phocytes from Pb-treated mice gave vari-
able results (87). In these experiments, Pb
levels of 0.08 to 0.4 mM enhanced the
response to SRBC while 2.0 mM did not
have any effect; the 10 mM dose resulted
in suppressed PFC numbers (87). Similar
results were obtained in experiments in
which splenocytes were exposed to Pb in
vitro and subsequently tested for their
humoral immune response to SRBC (87).
Statistically significant reduced PFC num-
bers to SRBC were observed in CD-1
mice following oral administration of
(C2H202)2Pb at doses of 13.75 or 137.5
ppm for 65 days or at a dose of 1375.0
ppm administered for 56 days (88), but a
dose-effect relationship was not observed
in other studies in which similar exposures
were used. For example, no effects were
noted following oral administration of 13,
130, or 1300 ppm ofPb for 70 days (68) or
doses of50, 200, or 1000 ppm administered
orally to BDF1 mice for 21 days (89). On
the contrary, significantly reduced PFC
numbers to SRBC and to the T-indepen-
dent antigens TNP-LPS or TNP-Ficoll
were reported for (C2H302)2Pb adminis-
tered at a single ip dose of 12 mg/kg body
weight (bw) to B6C3F, mice (90) or in rats
treated orally with 25 ppm of(C2H302)2Pb
for 70 days (86). Collectively, these results
indicated that the effects ofPb on the PFC
numbers were not consistent among studies
and varied considerably across the strains of
rodents used suggesting that genetic factors
might be involved.
Experimental data on the effects of Pb
on cellular parameters of the immune
response indicated that the B lymphocyte
might be affected following exposure to
Pb. A significantly reduced LPS-induced
splenocytic lymphoproliferative activity
was observed in B6C3F1 mice following
administration of a single ip dose of 12
mg/kg body weight (bw) of (C2H302)2Pb
(90). Similarly, significantly reduced LPS-
induced splenocytic proliferation was
observed in CBA/J mice exposed for 28
days to 2.0 and 10 mM of (C2H302)2Pb
added to drinkingwater while intermediate
concentrations of0.08 or 0.04 mM had no
effect (87). There were no dose-related
changes in the PHA- or ConA-induced
lymphoproliferative activity or in the MLC
activity (87). Similarly, the ConA-induced
lymphoproliferative activity ofsplenocytes
was not affected significantly in CBA/J mice
administered (C2H302)2Pb orally for 28
days doses of13, 130, or 1300 ppm (91). In
contrast, a significantly reduced T-cell blas-
togenic response to ConA was detected in
the offspring of Sprague-Dawley rats
exposed in utero to (C2H302)2Pb at doses of
25 or 50 ppm, suggesting that the develop-
ing fetus might be more susceptible to the
immunotoxic effects ofPb (85).
Decreased splenic and bone marrow
macrophage levels have been reported for
mice treated with a single ip dose (12
mg/kg bw) of (C2H302)2Pb (90). The
observed reduced macrophage numbers
may be responsible for the impaired ability
of CBA mouse peritoneal macrophages to
phagocytose SRBC following administra-
tion of 1300 ppm (C2H302)2Pb for 10
weeks (92). The effect on macrophage
function was dose dependent and possibly
strain dependent since lower doses of 5,
10, or 20 pg/kg bw administered ip or sin-
gle doses of 25, 50, or 100 pg/kg bw
administered orally increased the clearance
ofcolloidal carbon in NMRI mice (93).
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In contrast to the observed variable
effects ofPb on antibody production, the
effects ofPb on host resistance were charac-
terized bya uniformly reduced ability ofthe
host to combat infection. A single ip dose
of24 mg/kg bwof(C2H302)2Pb or doses of
5 and 12.5 mg/kg bw of lead nitrate
resulted in significantly reduced resistance to
Klebsiella pneumoniae and Salmonella
typhimurium in CD-1 mice (94,95).
Similarly, single intravenous (iv) doses of
8.5 or 20 mg/kg bw resulted in significantly
reduced resistance of rats to Salmonella
enteritidis and Escherichia coli endotoxin
and to S. epidermidis infection (96,97).
Likewise, concentrations of0.4 to 10 mM
of (C2H302)2Pb administered to mice in
the drinking water increased the mortality
rates in these animals when challenged
with a facultative intracellular bacterium,
Listeria monocytogenes (87).
In summary, the derivation ofNOAEL
and LOAEL values based on experimental
animal data is difficult since conflicting
results were reported for some ofthe para-
meters measured, including the PFC
response to SRBC. A LOAEL of 5 mg/kg
bw based on the observed uniformly
increased sensitivity to microbial infections
was derived for mice and rats following
either ip or iv administration ofsingle injec-
tions or the addition of Pb to drinking
water. It should be noted however, that the
experimental design did not allow for the
determination ofa potential NOAEL value
since relatively high doses ofPb were used in
these studies. This limitation and the lack of
data regarding levels ofPb in tissues do not
permit extrapolation of these findings to
humans. The increased frequency ofinfec-
tions observed in occupationally exposed
cohorts with low blood Pb levels (51 pg/dl)
and the reduced resistance to bacteria
observed in Pb-exposed animals strongly
indicated that the immune system can be
adversely affected by low levels ofPb. Thus,
additional studies using multiple doses ofPb
and data relating the doses administered to
levels in tissues are required to further define
asafe level ofexposure to Pb.
In VWts MechanisticStudies ofPb
The in vitro mechanistic studies also sug-
gested that the effect ofPb might be at the
B-cell level. But, unlike the suppressed
LPS-induced lymphoproliferative activity
observed in the exposed animals, an
enhancement ofthis activity was observed
in acute in vitroexposures.
For example, coculture of BALB/c or
CBA/J mouse splenocytes with (C2H302)2Pb
at concentrations of 10 or 100 pM for 3
days resulted in significantly increased
lymphoproliferative activity in response to
the LPS mitogen whereas 1 pM did not
have any effect (98). The lymphoprolifera-
tive response of the mouse T-cell
hybridoma DO.11.10 cell line to ConA
was not affected by PbCl2 added to cultures
at concentrations of 10 or 100 pM indicat-
ing that the T cell might be resistant to Pb
effects (99). Indeed, culture ofhuman PBL
with PbCI2 at concentrations of5.0, 10, or
100 pM for 7 days resulted in significantly
increased Ig secretion in unstimulated or
pokeweed mitogen (PWM)-stimulated cul-
tures whereas lower concentrations had no
effect on Ig secretion (100). The Pb-
induced enhancement of B-cell prolifera-
tion correlated with the enhancing effect of
Pb on the PFC numbers to SRBC (101).
The potential requirement of B-T cell
interaction for the enhancement of B-cell
differentiation was investigated by McCabe
and Lawrence (101) using membrane seg-
regated cultures. It was shown that B-T cell
interaction was not an absolute requirement
for the observed immunostimulation by Pb,
which suggests that Pb has the potential to
increase directly B-cell responses. However,
optimum levels of differentiation were
observedwhen B and T cells were incubated
simultaneously with Pb (101).
These results taken together suggested
that Pb might modulate the production of
helper factors leading to increased B-T
helper cell interactions (9,100). Using
antigen-specific T-cell clones, it was shown
that Pb preferentially altered a subset ofT-
helper cells. Indeed, it was shown that the
T-helper 1 activation was inhibited by Pb
while T-helper 2 activation was enhanced
(102). It is well documented, at least in the
mouse model, that T-helper 1 cells pro-
duce interleukin 2 (IL-2) and interferon
(INF)-gamma, whereas T-helper 2 cells
produce IL-4, IL-5, and IL-6 (101). This
differential influence ofPb may explain, at
least in part, the observed diverse in vivo
effects on immune responses.
Cadmium
EpidemiologicStudies ofCd
The commercially available Cd is largely
extracted during the production of other
metals including zinc, Pb, or copper.
Hazardous waste disposal sites are a large
source of the Cd concentrations found in
soil (approximately 4 ppb) and in water
(approximately 5 ppb) (103). The concen-
tration of Cd in air is very low (range
5-40 ng/m3), with concentrations in food
ranging from 2 to 40 ppb. Drinking water
contains on the average less than 1 ppb
(104). Cd concentrations in Great Lakes
water range from 16 ppt (Lake Huron) to
98 ppt (Lake Erie) (Table 1) (2). Human
exposure to Cd results from the ingestion of
contaminated food especially fish and, to a
much lesser extent, ofdrinkingwater (104).
Adult intake levels ofCd from food in the
United States were estimated to be 30
pg/day (105). Assuming a gastrointestinal
absorption of5 to 10%, the amount ofCd
absorbed from the diet would be approxi-
mately 1 to 3 pg/day. The estimated
dietary ingestion of Cd by the average
Canadian was reported to be 14.5 pg/day
(106). It should be pointed out, however,
that cigarettes contain large amounts ofCd
(1000-3000 ppb) and cigarette smoke may
contribute up to 3 pg/day to the smoker's
daily Cd intake (103).
The acute toxic effects ofCd are gener-
ally restricted to the lung, whereas the
effects following chronic Cd exposure in
humans are multisystemic and include
nephropathies, emphysematous alterations
in the lung, and cardiovascular diseases
(103). The U.S. EPA estimated oral
chronic RfDs for Cd are 0.001 and 0.0005
mg/kg/day for ingestion from food and
water, respectively. These are based on the
observed proteinuria in humans chroni-
cally exposed to Cd (107). The World
Health Organization recommends an
exposure limit of 10 pg/m3 for long-term
occupational exposure (108).
While a large body ofdata exist on the
in vivo and in vitro effects of Cd on the
immune system ofexperimental animals,
little data pertaining to occupationally
exposed cohorts could be located.
A significantly reduced activity (mea-
sured by chemiluminescence) was reported
for zymosan-activated neutrophils in the
peripheral blood ofworkers exposed to Cd
by inhalation for 1 to 14 years compared
to a reference (unexposed) group (109).
Kastelan et al. (110) described a dose-
dependent inhibition in PHA-induced
lymphocyte proliferation while Williams
et al. (111) did not detect any effects in
the PHA- or the purified protein deriva-
tive-induced lymphocyte proliferation in a
group ofpatients with chronic Cd disease.
Other parameters examined, including the
nitroblue tetrazolium reduction by blood
polymorphonuclear cells and the anti-
body-dependent cellular cytotoxicity, were
not affected in these patients (111).
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An increase in the incidence ofeczema
has been reported for one group ofworkers
with extensive exposure to Cd dust (112)
while a 1% nonirritating solution ofCdCI2,
used in routine patch tests in patients with
clinical manifestations of dermatitis and
eczema, did not result in allergic reactions
in these patients (113). This was true for
patients occupationally exposed to Cd or
for those patients without prior exposure
(113,114). Thus, the existing limited data
do not present strong evidence ofadverse
Cd-induced effects on the immune system
ofhumans. However, conclusions regard-
ing the potential adverse health effects of
Cd in humans should await further investi-
gations of cohorts either occupationally
exposed to Cd or following the ingestion of
Great Lakes fish.
Experimenal StudiesofCd in Vivo
The documented effects of Cd on the
immune system ofexperimental animals are
numerous and divergent (8). This reflects
the fact that many different chemical forms
of Cd were used in different species of
experimental animal models, with various
routes and duration of exposure and dose
regimens. Moreover, different assays, each
with a different sensitivity to detect
immunotoxic effects, were used.
The weight ofthe thymus was reported
to either decrease or remain unchanged in
the rat or mouse following exposure to Cd
(115,116). Similar findings were reported
for the spleen weight in the mouse model
(115,116). At the cellular level, a decrease
in the white blood cell counts and lympho-
cyte counts were observed in the gold fish
(Carassius auratus) following a whole body
exposure to CdCl2 at concentrations rang-
ing from 90 to 445 pg/l ofwater for peri-
ods of 3 and 6 weeks (117). No such
changes were reported in rainbow trout fol-
lowing a 12-week whole-body exposure to
low CdCl2 concentrations (0.7-6 pg/l of
water) (118). Whole-body exposure ofthe
Ranatadpole-a cold-blooded animal-to
CdCI2 concentrations ranging from 0.1 to
0.2 ppm for 6 weeks did not affect the
number of p+B lymphocytes in peripheral
blood, while CdCl2 concentrations four
times higher resulted in significantly
increased numbers ofthe p+B lymphocytes
(119). Similarly, increased lymphocyte
numbers were reported for rats treated
orally with 200 or 400 ppm ofCdCl2 for 6
months (120). On the contrary, oral
administration ofCd at doses of 3, 30, or
300 ppm to mice did not affect the number
ofB and T lymphocytes significantly while
five subcutaneous doses ofCdCl2 at levels
of0.5 or 1.0 mg/kg bw resulted in approxi-
mately 60% reduction in B-lymphocyte
levels compared to the control (116). The
total number of T lymphocytes was not
affected by this treatment regimen (116).
Thus, the route ofexposure to Cd greatly
influences the direction of effects on the
immune system, presumably due to the
different amounts ofCd absorbed by the
various routes ofexposure.
Cd has also been shown to affect non-
specific parameters ofthe immune response.
Uniformly decreased NK cell activity was
observed following administration ofvarious
doses of CdCl2 using different routes of
exposure (121). Furthermore, the number
ofmacrophages in the spleen and the bone
marrow were reduced significantly in
B6C3F1 mice administered a single ip dose
of 0.9 mg/kg bw of cadmium acetate
(C4H604Cd) (90). The dinical significance
of the observed decreased numbers of
macrophages is not clear since CdCl2
administered orally to B6C3F, mice for 90
days at doses of 10, 50, and 250 ppm
resulted in a significantly increased rather
than decreased phagocytic activity ofperi-
toneal macrophages when these were incu-
bated with K pneumoniae (122). However,
a significant reduction in the phagocytic
ability ofperitoneal macrophages was noted
when CD-1 mice were administered CdCI2
at a dose of300 ppm orally for 70 days; this
suggested that genetic factors may influence
the outcome ofeffects on the immune sys-
tem (91). No effect on the phagocytic activ-
ity ofperitoneal macrophages was detected
when doses of3 or 30 ppmwere used (91).
The effects ofCd on humoral immune
responses varied with the route of expo-
sure, the dose administered, and the end
point measured. In general, CdCl2 at doses
of 50 ppm administered to mice orally for
3 to 4 weeks did not affect the level oftotal
serum IgG (115). Similarly, administration
by inhalation of9.02 mg/m3 ofCd did not
affect the specific antibody response to
influenza virus in the mouse (123), or to
Trypanosoma lewisi in the rat (124).
However, increased production ofspecific
antibodies to Vibrio anguillarum was noted
in the rainbow trout as well as in the anti-
body levels to SRBC in the Rana tadpoles
followingwhole-body exposure to low levels
ofCdCl2 (118,119). In mice, doses of 5,
10, or 50 ppm ofCdCI2 administered orally
for 26 days increased the number ofPFC to
the hapten-carrier dinitrophenol-Ficoll
(DNP-Ficoll) (125); moreover, a dose of
5.9 mg/kg bw administered sc for 7 days
increased the number of PFC to the hap-
ten-carrier trinitrophenol-lipopolysaccaride
(TNP-LPS) (126).
The direction ofeffects of Cd on the
PFC response to SRBC varied with dose,
the route ofexposure, and the animal model
used. For example, oral administration of
CdCl2 at doses of 3 or 30 ppm to CD-I
mice had no effect, whereas a dose of300
ppm resulted in increased PFC numbers
(68). Furthermore, a single dose of0.15 mg
ofCdCl2 administered orally to CD-1 mice
resulted in a 25% decrease in PFC numbers
to SRBC (91). However, the same dose
administered ip (127) or single doses of
1.48, 2.96, 5.91, or 1.81 mg/kg bwadmin-
istered im had no effect (128). Similarly,
the studies by Malave and De Ruffino
(129) indicated that a dose of 50 ppm of
CdCl2 administered orally to CD-I mice
for 3 to 9 weeks resulted in an increase of
the PFC numbers. Doses of 10, 50, or 250
ppm administered to B6C3F, mice for 90
days had no detectable effect on the PFC
numbers (122).
Cd has also been reported to alter the
cellular immune response in rodents.
Splenocytes of mice exposed to CdCl2 for
10 weeks at doses of 3 and 30 ppm dis-
played no modifications in their responses
to LPS while at a dose of 300 ppm they
increased the blastogenic response to LPS
significantly (91). The blastogenic response
oflymphocytes to other mitogens varied.
For example, the blastogenic response of
lymphocytes to PHA, ConA, and PWM
was significantly reduced when mice were
treated orally with daily doses of 10 or 250
ppm ofCdCl2 for a period of90 days; at an
intermediate concentration of50 ppm, the
response to these mitogens was not affected
(122). The MLC response ofleukocytes
was suppressed following ip administration
of2 mg/kg bw ofCdCl2 for 40 days (130).
In other experiments whereby mice were
treated orally with daily doses of50 or 200
ppm ofCdCl2 for a period ranging from 3
to 9 weeks or with C4H6CdO4 at doses of
300 or 600 ppm for 10 weeks, the response
to PHA and ConA were significantly
increased (129,131).
Specificcell-mediated immune responses
were also shown to be affected by Cd. In
mice, the delayed-type hypersensitivity
(DTH) response to SRBC was decreased
following oral administration of 65.2
mg/kg bw for 14 days (132); however, in
another series ofexperiments, neither the
DTH response to SRBC (132) or to KLH
(118) in the mouse model or to dini-
trofluorobenzene (DNFB) in the rat model
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(124) were modified following treatment
with CdC12-
Data on the effects of CdCl2 on host
resistance indicated that higher Cd levels
may compromise resistance to infectious
agents while lower doses, depending on the
route ofexposure, may increase the host's
ability to resist infection or may not have a
significant effect. For example, a decreased
resistance of B6C3F1 mice to influenza
and herpes (HSV-1, HSV-2) viruses, and
to L. monocytogenes was observed following
oral administration of 10, 50, or 250 ppm
of CdCI2 for 90 days (122). Similarly,
reduced resistance to Streptococcus enteritidis
and Escherichia coli was observed following
exposure of rats to a single injection of6.0
mg/kg bw of C4H6O4Cd (96). On the
contrary, exposure ofmice by inhalation to
9.02 mg/in3 of Cd for short periods
increased the resistance to influenza virus
(123) and Trypanosoma lewisi(124).
In summary, Cd-induced immunomodu-
lation includes quantitative and functional
effects on the phagocytic lineage ofcells
and NK cells and the antibody response to
various antigens. However, the direction of
the observed effects was not uniform across
strains and varied with the route ofexpo-
sure. In general, exposure to Cd reduced
the ability ofthe animal to combat infec-
tion at a LOAEL = 10 ppm. Clearly, the
derivation of a NOAEL based on data
available from the in vivo animal studies is
not possible, and further carefully designed
multiple dose studies are needed.
In VitroMechanisticStudies ofCd
In vitro systems in which cells are exposed
to heavy metals can be useful in elucidating
the mechanisms whereby heavy metals pro-
duce their immunotoxic effects. In such
systems, knowledge ofthe levels ofCd that
are cytotoxic to cells is of importance. In
this respect, CdCl2 concentrations of0.1,
1.0, or 10.0 ppm were not cytotoxic to
mouse splenocytes whereas concentrations
of 1000 ppm resulted in cytotoxicity (133).
Using an in vitro system, it was shown
that the NK cell activity and antibody-
dependent cellular cytotoxicity ofhuman
PBL were suppressed in a dose- and time-
dependent manner when incubated with
CdCI2 (134,135). The cytotoxic effects
were observed only when Cd was added to
the cell culture very early in the assay.
Moreover, preincubation of the human
PBL with IL-2 for 4 days did not abrogate
the Cd-mediated effects, suggesting that the
effects of cadmium could be on an early
signaling pathway in these cells (134).
Data on the in vitro effects of Cd on
humoral immune responses indicated that
Cd had an enhancing effect. For example,
CdCI2 added to spleen mononuclear cell
cultures ofBALB/c mice at quantities of4
to 40 pM for 5 days, resulted in a signifi-
cantly increased PFC response to SRBC
(136). Similarly enhanced PFC numbers
to SRBC were observed in cultures of
CBA/J mice or when spleen mononuclear
cells from either CBA/J or BALB/c mice
were incubated with CdCI2 at quantities of
0.1, 1.0, 10.0, or 100 iM (9,137). A
significant enhancement was also observed
for the PFC numbers to the T-indepen-
dent antigen DNP-Ficoll when BALB/c
mouse mononuclear cells were cultured
with 0.04 mM of CdCI2, whereas
significantly decreased PFC numbers were
detected at doses of0.1 or 0.2 mM (138).
In contrast to the observed enhancing
effect ofCd on PFC numbers, a uniformly
decreased mitogen-induced lymphoprolifer-
ative activity was obtained when Fischer
344 rat splenocytes were cocultured with
0.05 to 500 pM of CdCI2 (139). A
significantly decreased proliferative activity
in response to PWM and purified protein
derivative was also observed when human
PBL were incubated with 25 or 50 pM for
3 days (140). Likewise, the lymphoprolifer-
ative response ofConA-stimulated human
PBL was significantly decreased in co-
cultures with 1 to 100 pM of Cd (141).
The observed inhibition was dose depen-
dent and detected onlywhen cadmium was
added to cultures concurrently. A marginal
inhibitory effect was observed ifthe metal
was added after the first hour of cell cul-
ture, suggesting that cadmium could affect
an early step in the mitogen-induced stim-
ulation (141). When CdCl2 in quantities
of 0.05 to 1.0 pM were cultured with
pooled human PBL for 7 days, a dose-
independent increased proliferation ofthe
unstimulated (no mitogen) cells and
increased Ig levels in culture supernatants
was observed, whereas PWM-induced Ig
secretion in culture supernatants was not
affected by Cd (100). The significance of
these in vitro findings is not clear since a
considerable interindividual variability in
PWM-activation and Ig secretion was
observed when each subject's lymphocytes
were tested separately; this suggests that
genetic factors may play a role in the
observed variable effects ofcadmium (99).
Thus, data derived from the in vitro
studies demonstrated that Cd is a potential
immunomodulator at noncytotoxic levels
ofexposure. From the mechanistic point of
view, it has been proposed that Cd may
disrupt cell to cell contact between subpop-
ulations oflymphocytes (142) and thus
interfere with cell signaling mechanisms
(143). The activation oflymphocytes for
signal transduction includes hydrolysis of
phosphatidylinositol-4,5-diphosphate to
diacylglycerol and inositol 1,4,5-triphos-
phate (IP3), which in turn activate protein
kinase C (PKC) and stimulate the release of
calcium from intracellular compartments
(141). Two independent studies have
demonstrated that hydrolysis of IP3 was
decreased up to 50% in the presence ofcad-
mium (134,141). Another mechanism by
which Cd may induce its immunotoxic
effects is probably related to interference
with the role ofcalcium. It has been demon-
strated that Cd added to cultures inhibited
the proliferation oflymphocytes when stim-
ulated with phorbol myristate acetate an
activator of PKC (141). These results are
suggestive ofa potential action ofCd down-
stream to PKC or of a direct Cd-induced
inhibition of PKC (144). Moreover, cad-
mium has been demonstrated to be an
inhibitor ofcalcium channels (142) and a
competitorofCa2+ ions resulting in interfer-
ence with Ca2+- dependent enzymatic func-
tions such as calmodulin (145). Overall, the
mechanism ofCd-induced immunomodu-
lation remains elusive, and further mecha-
nistic studies are required to clearly define
the potential adverse immunotoxic effects of
Cd on human health.
Future Considerations
There is a need to design protocols using
multiple doses, including low-dose expo-
sures, and to perform experiments with
built-in quality assurance and quality con-
trol methods. Further research is required
to define the potential interactive effects of
the heavy metals present in the Great Lakes
basin, which have been shown to accumu-
late in fish tissues. Parallel to these require-
ments there is an urgent need to establish a
set of immunologic assays for use in
humans and to include these assays in
future designs ofepidemiologic studies in
cohorts who are exposed to these metals
either inadvertently, occupationally, or
through ingestion of contaminated fish
from the Great Lakes.
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